Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox&
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  Multiple new research abstracts suggest walnuts may have ... From their impact on colon cancer and certain aspects ... gut health and vascular health, the research findings presented ... of walnuts, inner workings. Running March 28 through April ... meeting attracts an international audience of over 14,000 leading ...
(Date:3/30/2015)... -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... Yale University, on March 27 released pre-clinical data on ... an oral presentation by Professor Gil Mor ... nd Annual Scientific Meeting of the Society of ... In both in vitro and in ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated ... committed to the fostering and monetization of intellectual ... VTech,  Case No. 3:13-cv-03494-M and  Spherix v. Uniden ... States District Court for the Northern District of ... regarding Spherix v. Verizon, Case No. ...
(Date:3/30/2015)... -- Richmond Pharmacology nimmt weltweit den ... das erste Zentrum weltweit, das in Zusammenarbeit mit ... London in einer weltweiten ... einem Patienten begonnen hat. Das Therapeutikum wurde für ... einer seltenen Herz- und Nervenkrankheit. ...
Breaking Biology Technology:New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
... June 16 Naviscan PET Systems(R), a company,specializing ... the Society of Nuclear Medicine,s Annual Meeting, new ... cancer management. The PEM,Flex(TM) Solo II is a ... for the breast application known as positron,emission mammography, ...
... Medullary Thyroid Cancer Planned to Initiate This Summer, ... Inc. (Nasdaq: EXEL ) announced today that ... (FDA) have reached agreement on the phase 3,registration ... targeting,MET, RET, and VEGFR2, via the Special Protocol ...
... NDC #58177-320-04 & 58177-330-04 ... Lot Numbers listed below, ST. ... recalled specific additional lots of morphine,sulfate 60 mg extended release tablets, ... a precaution, due to the,possible presence of oversized tablets. Oversized tablets ...
Cached Biology Technology:Naviscan's PEM Flex(TM) Detects Smallest Cancers Better Compared to MRI in an Independent Study 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... Brine water that flows back from gas wells in ... times more salty than seawater, with high contents of ... consistent with brines formed during the Paleozoic era, a ... Penn State,s Department of Geosciences found. The study indicates ...
... of Energy,s National Renewable Energy Laboratory (NREL) will partner ... a five-year, $7 million effort to economically produce drop-in ... the federal laboratory announced today. The work will ... (CRADA) between NREL and Johnson Matthey. "It,s a ...
... The Hass Avocado Board (HAB) is supporting ... benefits of consuming fresh avocados to human health ... investigate the relationship between avocado consumption and risk ... in weight management and diabetes, and avocados, ability ...
Cached Biology News:Analysis of Marcellus flowback finds high levels of ancient brines 2NREL and Johnson Matthey announce 5-year collaboration on biofuels 2Hass Avocado Board study published in Food & Function journal 2
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
Spaced cover glasses to promote effective hybridization...
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
... new D-LUX Detection Platform combines robust ... the most sensitive, specific, and cost-effective ... D-LUX Detection Platform offers exceptional performance ... TaqMan probes, high signal/background ratio, and ...
Biology Products: